Navigation Links
VaxGen Issues Rebuttal to MedCap Letter
Date:3/25/2008

y new institutional investors who would

otherwise be attracted by Raven's technology.

VaxGen would note that, in arriving at the terms offered to Raven

stockholders in the proposed merger, it, together with its advisors

at Lazard, used a number of methodologies to value Raven, all of

which showed the proposed transaction to be fair to VaxGen

stockholders based on VaxGen's stock price at the time. Given the

fall in VaxGen's stock price since then, the valuation placed on

Raven's assets is even less demanding, especially in light of recent

transactions in the oncology monoclonal antibody (MAb) arena.

3. ISS' finding that the transaction lacks strategic rationale is, in

the company's view, flawed. It appears to be based on the limited

perspective that VaxGen is a vaccine company whereas Raven is an

antibody company. In fact, most of VaxGen's vaccine programs were

based on recombinant proteins of which monoclonal antibodies are a

subset. As evidence of this, it is noteworthy that VaxGen was the

technology partner and largest founding shareholder of Celltrion,

one of the largest independent manufacturers of mammalian cell

recombinant proteins, including monoclonal antibodies. Further, as

previously disclosed, a number of VaxGen scientists are already

engaged on Raven programs under arms-length contractual

arrangements, suggesting that synergies between the two merged

companies indeed do exist. In reality, VaxGen's later-stage drug

development expertise is highly complementary to Raven's discovery

and early stage capabilities.

4. ISS' has estimated that liquidation of VaxGen would result in

proceeds with a present value of only $0.49 per share. We do not


'/>"/>

SOURCE VaxGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. VaxGen Files 2006 Financial Statements and Provides Cash Update
2. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
3. VaxGen Files First Quarter 2007 Financials
4. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
5. VaxGen Files Last Outstanding Periodic Report With SEC
6. VaxGen Addresses MPM Claims in Letter to Stockholders
7. VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board
8. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
9. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
10. VaxGen to Present at the 10th Annual BIO CEO and Investor Conference
11. VaxGen Reports Financial Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ... capital and general corporate purposes. Under ...
(Date:12/24/2014)... 2014 SoundConnect’s ... to introduce cutting edge communication technology, provide ... of platform upgrades. This webinar series demonstrates ... in their quest to leverage web conferencing’s ... to SoundConnect’s Marketing Manager, Seanna Baumgartner, “Our ...
(Date:12/24/2014)... December 24, 2014 The report expects ... 19.7% by 2019. It also provides a carefully analyzed ... and challenges for the market. , Full Copy of ... report, the global market for cell expansion will keep ... It expects this growth to be driven by rapid ...
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3
... , ... ... ... ...
... , ... symposium to unveil study aimed at ensuring global food security and sustainability. , ... Washington (PRWEB) -- On ... sustainably double agricultural output and improve storage and distribution to eliminate the global productivity ...
... ... ... ... ...
Cached Biology Technology:Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 2Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 3Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 4Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 5Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 6Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 7Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 8Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 9Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 10Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 11Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 12Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 13Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 14Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 15Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 16Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 17Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 18Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 19Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 20Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 21Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 22Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 23Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 24Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 25Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 26Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 27Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 28Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 29Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 30Gloabl Harvest Initiative: Taking Down Fences To Meet Future Needs 2Gloabl Harvest Initiative: Taking Down Fences To Meet Future Needs 3Tianyin Pharmaceutical Co., Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing on March 9 2Tianyin Pharmaceutical Co., Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing on March 9 3Tianyin Pharmaceutical Co., Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing on March 9 4Tianyin Pharmaceutical Co., Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing on March 9 5
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a ... $2.3 million in Series A1 funding led by UK-based ... also participated in the investment round. "We ... healthcare community adopts next-generation sequencing and seeks new approaches ... Reid Robison , MD MBA, and CEO of ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... physics now becomes easier with the formal launch of ... from the American Physical Society. Physics will highlight and ... publications of Physical Review Letters and the ... will keep readers apprised of important new articles as ...
... information, as detectives, historians and identity thieves well ... treasures, University of Delaware researchers have found. ... UD,s Delaware Biotechnology Institute analyzed the cellular waste ... discovered formerly hidden relationships between genes and the ...
... of Oregon,s Climate Leadership Initiative, the need to address ... Bob Doppelt says in his new book requires a ... The 240-page book published by London-based Earthscan Publications Ltd. ... private sector, but its content is accessible to "anyone ...
Cached Biology News:American Physical Society announces Physics, a new, free, online publication 2Using novel tool, UD researchers dig through cell 'trash' and find treasure 2Using novel tool, UD researchers dig through cell 'trash' and find treasure 3'No time to lose' to start thinking sustainability 2
... Disposable. Virgin, optically clear polystyrene ... and alphanumeric coordinates for cell counting. ... number is a new product number, ... number. If showing no availability yet, ...
... CellBIND surface is produced by a ... more hydrophilic surface giving more consistent, ... and yields. CellBIND enhances cell attachment ... reduced serum or serum-free medium. • ...
Cell Culture Flask, 75 cm, treated polystyrene...
... Disposable. Virgin, optically clear polystyrene ... and alphanumeric coordinates for cell counting. ... number is a new product number, ... number. If showing no availability yet, ...
Biology Products: